| 2024年中报 | 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 代谢及消化系统疾病治疗领域核心产品(元) | 1,398,000,000.00 | 2,824,000,000.00 | 1,504,000,000.00 | 2,883,000,000.00 | 1,383,000,000.00 |
| 抗感染疾病治疗领域核心产品(元) | 1,453,000,000.00 | 4,340,000,000.00 | 3,318,000,000.00 | 8,582,000,000.00 | 3,629,000,000.00 |
| 抗肿瘤治疗领域核心产品(元) | 4,051,000,000.00 | 7,638,000,000.00 | 3,699,000,000.00 | 5,522,000,000.00 | 2,550,000,000.00 |
| 西药和原料药中间体等(元) | 560,000,000.00 | 1,271,000,000.00 | 654,000,000.00 | 1,248,000,000.00 | 633,000,000.00 |
| 血液系统疾病治疗领域核心产品(元) | 1,026,000,000.00 | 1,677,000,000.00 | 839,000,000.00 | 2,115,000,000.00 | 1,095,000,000.00 |
| 中枢神经系统疾病治疗领域核心产品(元) | 492,000,000.00 | 1,184,000,000.00 | 551,000,000.00 | 1,003,000,000.00 | 422,000,000.00 |
| 营业成本(元) | |||||
| 代谢及消化系统疾病治疗领域核心产品(元) | 341,000,000.00 | 639,000,000.00 | 326,000,000.00 | 614,000,000.00 | 289,000,000.00 |
| 抗感染疾病治疗领域核心产品(元) | 417,000,000.00 | 2,173,000,000.00 | 1,462,000,000.00 | 4,007,000,000.00 | 1,701,000,000.00 |
| 抗肿瘤治疗领域核心产品(元) | 853,000,000.00 | 1,566,000,000.00 | 757,000,000.00 | 1,074,000,000.00 | 493,000,000.00 |
| 西药和原料药中间体等(元) | 417,000,000.00 | 910,000,000.00 | 468,000,000.00 | 921,000,000.00 | 476,000,000.00 |
| 血液系统疾病治疗领域核心产品(元) | 645,000,000.00 | 1,042,000,000.00 | 507,000,000.00 | 1,364,000,000.00 | 706,000,000.00 |
| 中枢神经系统疾病治疗领域核心产品(元) | 53,000,000.00 | 107,000,000.00 | 50,000,000.00 | 101,000,000.00 | 41,000,000.00 |
| 毛利(元) | |||||
| 代谢及消化系统疾病治疗领域核心产品(元) | 1,057,000,000.00 | 2,185,000,000.00 | 1,178,000,000.00 | 2,269,000,000.00 | 1,094,000,000.00 |
| 抗感染疾病治疗领域核心产品(元) | 1,036,000,000.00 | 2,167,000,000.00 | 1,856,000,000.00 | 4,575,000,000.00 | 1,928,000,000.00 |
| 抗肿瘤治疗领域核心产品(元) | 3,198,000,000.00 | 6,072,000,000.00 | 2,942,000,000.00 | 4,448,000,000.00 | 2,057,000,000.00 |
| 西药和原料药中间体等(元) | 143,000,000.00 | 361,000,000.00 | 186,000,000.00 | 327,000,000.00 | 157,000,000.00 |
| 血液系统疾病治疗领域核心产品(元) | 381,000,000.00 | 635,000,000.00 | 332,000,000.00 | 751,000,000.00 | 389,000,000.00 |
| 中枢神经系统疾病治疗领域核心产品(元) | 439,000,000.00 | 1,077,000,000.00 | 501,000,000.00 | 902,000,000.00 | 381,000,000.00 |
| 毛利率(%) | |||||
| 代谢及消化系统疾病治疗领域核心产品(%) | 75.61 | 77.37 | 78.32 | 78.70 | 79.10 |
| 抗感染疾病治疗领域核心产品(%) | 71.30 | 49.93 | 55.94 | 53.31 | 53.13 |
| 抗肿瘤治疗领域核心产品(%) | 78.94 | 79.50 | 79.54 | 80.55 | 80.67 |
| 西药和原料药中间体等(%) | 25.54 | 28.40 | 28.44 | 26.20 | 24.80 |
| 血液系统疾病治疗领域核心产品(%) | 37.13 | 37.87 | 39.57 | 35.51 | 35.53 |
| 中枢神经系统疾病治疗领域核心产品(%) | 89.23 | 90.96 | 90.93 | 89.93 | 90.28 |
| 收入构成(%) | |||||
| 代谢及消化系统疾病治疗领域核心产品(%) | 15.57 | 14.91 | 14.24 | 13.50 | 14.24 |
| 抗感染疾病治疗领域核心产品(%) | 16.18 | 22.92 | 31.41 | 40.19 | 37.37 |
| 抗肿瘤治疗领域核心产品(%) | 45.11 | 40.34 | 35.01 | 25.86 | 26.26 |
| 西药和原料药中间体等(%) | 6.24 | 6.71 | 6.19 | 5.84 | 6.52 |
| 血液系统疾病治疗领域核心产品(%) | 11.43 | 8.86 | 7.94 | 9.90 | 11.27 |
| 中枢神经系统疾病治疗领域核心产品(%) | 5.48 | 6.25 | 5.22 | 4.70 | 4.35 |
| 毛利构成(%) | |||||
| 代谢及消化系统疾病治疗领域核心产品(%) | 16.90 | 17.48 | 16.84 | 17.10 | 18.22 |
| 抗感染疾病治疗领域核心产品(%) | 16.57 | 17.34 | 26.53 | 34.47 | 32.10 |
| 抗肿瘤治疗领域核心产品(%) | 51.14 | 48.59 | 42.06 | 33.51 | 34.25 |
| 西药和原料药中间体等(%) | 2.29 | 2.89 | 2.66 | 2.46 | 2.61 |
| 血液系统疾病治疗领域核心产品(%) | 6.09 | 5.08 | 4.75 | 5.66 | 6.48 |
| 中枢神经系统疾病治疗领域核心产品(%) | 7.02 | 8.62 | 7.16 | 6.80 | 6.34 |